Fine-Tuning Stem Cell Therapy to Repair the Heart
|
By LabMedica International staff writers Posted on 27 Mar 2013 |
Stem cells have the potential to grow into a range of cell types, including heart cells. Researchers are now trying to refine the process of repairing and regenerating heart tissue damaged by a heart attack with stem cells.
A recent study from Cedars-Sinai Heart Institute (Los Angeles, CA, USA) suggests that stem cells may, undeniably, heal damaged hearts. The researchers treated 17 heart attack survivors with an infusion of stem cells taken from their own hearts. One year later, the amount of scar tissue had shrunk by about 50%. These findings look dramatic, but investigators are wondering if they an indication that they are close to perfecting stem cell therapy.
“This is a field where, depending on which investigator you ask, you can get incredibly different answers,” Dr. Richard Lee, professor of medicine at Harvard Medical School (Boston, MA, USA), and a leading specialist on stem cell therapy, reported in the March 2013 issue of Harvard Women’s Health Watch. “The field is young. Some studies show only modest or no improvement in heart function, but others have shown dramatically improved function. We’re waiting to see if other doctors can also achieve really good results in other patients.”
New research is generating contrary findings in part, because researchers use diverse approaches to harvest and use stem cells. Some are gathered from the bone marrow of donors, others from the recipient’s own heart. It is not evident which approach works optimally. “Some investigators think this is just a few years away,” concluded Dr. Lee. “And then there are others who feel that there is much more work to be done.”
Presently, stem cell therapy is available only to individuals who participate in a research trial.
Related Links:
Cedars-Sinai Heart Institute
Harvard Medical School
A recent study from Cedars-Sinai Heart Institute (Los Angeles, CA, USA) suggests that stem cells may, undeniably, heal damaged hearts. The researchers treated 17 heart attack survivors with an infusion of stem cells taken from their own hearts. One year later, the amount of scar tissue had shrunk by about 50%. These findings look dramatic, but investigators are wondering if they an indication that they are close to perfecting stem cell therapy.
“This is a field where, depending on which investigator you ask, you can get incredibly different answers,” Dr. Richard Lee, professor of medicine at Harvard Medical School (Boston, MA, USA), and a leading specialist on stem cell therapy, reported in the March 2013 issue of Harvard Women’s Health Watch. “The field is young. Some studies show only modest or no improvement in heart function, but others have shown dramatically improved function. We’re waiting to see if other doctors can also achieve really good results in other patients.”
New research is generating contrary findings in part, because researchers use diverse approaches to harvest and use stem cells. Some are gathered from the bone marrow of donors, others from the recipient’s own heart. It is not evident which approach works optimally. “Some investigators think this is just a few years away,” concluded Dr. Lee. “And then there are others who feel that there is much more work to be done.”
Presently, stem cell therapy is available only to individuals who participate in a research trial.
Related Links:
Cedars-Sinai Heart Institute
Harvard Medical School
Latest BioResearch News
- New Molecular Insights Support Diagnosis of Hodgkin Lymphoma
- Epigenetic Signals and Blood Markers Aid Chronic Fatigue Syndrome Diagnosis
- Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
Channels
Clinical Chemistry
view channel
Blood Test Detects Testicular Cancer Missed by Standard Markers
Testicular cancer most often affects adolescents and young adults and is highly treatable when found early. Diagnosis can be difficult when tumors do not produce sufficient levels of standard blood-based... Read more
Routine Blood Tests Identify Biomarkers Linked to PTSD
Post-traumatic stress disorder (PTSD) is associated with a range of chronic physical health conditions and affects multiple organ systems. Clinical laboratories routinely measure blood analytes that reflect... Read moreMolecular Diagnostics
view channel
Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
Despite decades of effective drug regimens, tuberculosis remains the leading cause of death from an infectious disease, driven in part by limited access to accurate, rapid testing. Conventional diagnostics... Read more
Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
Differentiating schizophrenia from bipolar I disorder in symptomatic patients is challenging because early presentations often overlap. Current diagnostic pathways rely heavily on subjective assessments... Read more
Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
Sepsis remains a time-critical condition in which rapid risk assessment is often hindered by reliance on centralized laboratory testing. The global burden is substantial, with an estimated 166 million... Read more
Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. Missed detection at this stage can delay evaluation and management... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read moreTechnology
view channel
Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
Risk stratification for breast cancer remains imprecise, as population-based models and breast density can over- or underestimate individual risk, potentially leading to over- or under-screening.... Read more







